VRK3 is a member of the vaccinia-related kinase family (Manning et al. 2002), which comprises a group of three proteins, of which two, VRK1 and VRK2, are catalytically active. VRK3 has substitutions in key residues within its catalytic domain and is under some conditions a pseudokinase without kinase activity (Nichols and Traktman 2004). The biological effects of VRK3 are mediated by protein-protein interactions. VRK3 can deactivate mitogen-activated protein (MAP) kinase signaling in the nucleus by activating phosphatases such as VHR, which dephosphorylates extracellular signal-regulated protein kinase (ERK), and reduces its ability to activate transcription. VRK3 kinase activity can be induced by its interaction with BAF that modifies the conformation of the vrk3 n-terminal domain (Park et al. 2015).
VRK3 Gene Expression
The human VRK3 gene is located in chromosome 19q13.33, has...
- Gozdz A, Vashishta A, Kalita K, Szatmari E, Zheng JJ, Tamiya S, et al. Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases. J Neurochem. 2008;106:2056–67. https://doi.org/10.1111/j.1471-4159.2008.05550.xCrossRefPubMedPubMedCentralGoogle Scholar
- Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure. 2009;17:128–38. https://doi.org/10.1016/j.str.2008.10.018.CrossRefPubMedPubMedCentralGoogle Scholar